Online inquiry

IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6703MR)

This product GTTS-WQ6703MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets SLC34A2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001300868.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3177
UniProt ID Q14542
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ6703MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11420MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ8173MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HL161
GTTS-WQ9870MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA K7153A
GTTS-WQ6680MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ3845MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BCD-054
GTTS-WQ15923MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ2627MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 592
GTTS-WQ2635MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 592
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW